HL-91-Technetium-99m: A new marker of viability in ischemic myocardium
| Autor: | Robert D. Okada, Gerald Johnson, Delia Beju, Lara R. Carlson, Kiem N. Nguyen |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Male
medicine.medical_specialty Ischemic myocardium Myocardial Ischemia chemistry.chemical_element In Vitro Techniques Technetium Rats Sprague-Dawley Coronary Circulation Sodium Cyanide Internal medicine Oximes Ventricular Pressure Animals Medicine Radiology Nuclear Medicine and imaging Radionuclide Imaging Creatine Kinase Severe injury biology business.industry Myocardium Hemodynamics Heart Organotechnetium Compounds Hypoxia (medical) Rats Microscopy Electron chemistry Cardiology biology.protein Creatine kinase Radiopharmaceuticals medicine.symptom Cardiology and Cardiovascular Medicine business Nuclear medicine Technetium-99m Triphenyltetrazolium chloride |
| Zdroj: | Journal of Nuclear Cardiology. 6:306-315 |
| ISSN: | 1071-3581 |
| DOI: | 10.1016/s1071-3581(99)90043-0 |
| Popis: | Technetium 99m-HL91 is a new hypoxia imaging agent that demonstrates increased uptake in ischemic, viable myocardium. This study was performed to determine whether HL91 is taken up by nonviable myocardium.Twenty-three Krebs-Henseleit buffer-perfused, isolated rat hearts were studied. Tc-99m-HL91 300 microCi was infused over 10 minutes, followed by a 60-minute clearance. Myocardial activity was monitored by use of an NaI crystal. Four groups were studied: control (flow = 12 mL/min, n = 7), low flow (flow = 1 mL/min, n = 6), no flow/reflow (60 minutes no flow/60 minutes reflow before Tc-99m-HL91 infusion, flow = 12 mL/min, n = 5), and cyanide-treated (before Tc-99m-HL91 infusion, flow = 12 mL/min, n = 5). Injury was assessed by creatine kinase, transmission electron microscopy, and triphenyltetrazolium chloride.Control (no injury) and cyanide-treated (severe injury) hearts demonstrated low uptake (6.3+/-0.5 mean+/-SEM and 5.7+/-1.2 microCi, respectively) and low 60-minute retention (13.8%+/-2.2% and 13.7%+/-3.9%, respectively). Low-flow hearts (minimal injury) demonstrated markedly increased uptake (43.5+/-2.8 microCi, P.01) and increased 60-minute retention (33.2%+/-2.9%, P.01) compared with control. No-flow/reflow hearts (moderate injury) demonstrated intermediate uptake (8.7+/-0.5 microCi, P.05 to control), although retention was not significantly different (18.9%+/-3.5%, P = ns). Severely and rapidly injured myocardium demonstrated Tc-99m-HL91 peak uptake and retention indistinguishable from normal. Moderately injured myocardium demonstrated uptake intermediate between severely injured and low-flow-induced ischemic, viable myocardium.Thus Tc-99m-HL91 is not taken up or retained in nonviable and irreversibly injured myocardium. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink